Skip to content

Implant Phenotype Modification Via GBR and ADM

Phenotype Modification Via Guided Bone Regeneration and Acellular Dermal Matrix Simultaneous to Delayed Implant Placement: A Double Arm Randomized Controlled Clinical Trial.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07082244
Enrollment
40
Registered
2025-07-24
Start date
2025-06-01
Completion date
2027-09-01
Last updated
2026-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Horizontal Ridge Deficiency

Brief summary

Single implant sites with bone loss can often be managed by bone grafting alone. The purpose of this study is to determine whether putting a soft tissue graft substitute over the bone graft will provide an increased benefit for improving the health, appearance, and stability of the bone and gums surrounding the implant.

Detailed description

The study will treat patients that need a single implant at a previously edentulous site (\>3 months post extraction) that requires phenotypic modification. These patients will receive an implant with simultaneous GBR, with half of the participants also receiving an ADM graft.

Interventions

PROCEDUREDental implant placement

Participants will have a dental implant placed at a toothless site

PROCEDUREGuided bone regeneration with collagen membrane

Participants will receive guided bone regeneration at a toothless site with bone substitute and a collagen membrane.

PROCEDUREGuided bone regeneration with acellular dermal matrix.

Participants will receive guided bone regeneration at a toothless site with bone substitute and an acellular dermal matrix.

Sponsors

University of Michigan
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years. * Subjects with a physical status of systemically healthy or suffering from mild to moderate, but well-controlled disease; American Society of Anesthesiology (ASA) I or II. * Subjects must have one edentulous region, with at least 3 months of healing post-extraction, in the esthetic zone of the maxilla or the premolar and canine region of the mandible. This region includes the maxillary premolars, canines, and incisors. * Subjects must have a full mouth plaque and bleeding score of less than or equal to 20%, measured at four sites per tooth. * The patients should have a thin periodontal phenotype; bucco-lingual ridge thickness greater than 6mm. * Seibert class I deficiency (Seibert, 1983) * Patients willing to sign the informed consent.

Exclusion criteria

* Presence of uncontrolled and/or untreated periodontal disease. * Patients currently smoking cigarettes, cannabis, and electronic cigarettes. * Subjects taking medications known to impact bone metabolism or have the capacity to affect wound healing. These drugs include bisphosphonates, corticosteroids, parathyroid hormone, RANKL inhibitors, past exposure to head and neck radiation, chemotherapy within the last 12 months, among others. * Subjects with systemic diseases that impact bone metabolism and wound healing. Namely, osteoporosis, osteopenia, hyperparathyroidism, Paget's disease. * Allergy to the graft materials. * Pregnant subjects or individuals who self-report as attempting to become pregnant. * Patient's unwilling to sign the informed consent.

Design outcomes

Primary

MeasureTime frameDescription
Horizontal linear change of the buccal bone6 monthsRadiographic changes of bone level in mm based on cone-beam computed tomography

Secondary

MeasureTime frameDescription
The volumetric changes of the facial soft tissue6 monthsVolumetric changes in mm\^3 based on intraoral digital scans
The vascular changes of the facial soft tissue6 monthsVascular changes in mm\^3 based on ultrasound scans
Peri-implant health, as defined by clinical attachment level.6 monthsChanges in clinical attachment level measurements in mm
Patient-reported morbidity, satisfaction and comfort using a visual analogue scale (VAS)6 monthsDifference in survey results
Clinician-reported overall treatment effectiveness6 monthsScale from 1 (Poor) to 5 (Excellent)
Histological bone density6 monthsHistomorphometry

Countries

United States

Contacts

CONTACTDavid Dunbar, DDS
dgdunbar@umich.edu734-763-3346
CONTACTAlice Ou, RDH, MS
aliceou@umich.edu734-763-3346
PRINCIPAL_INVESTIGATORMuhammad Saleh, BDS, MSD

University of Michigan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 31, 2026